Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE …
M Bassetti, R Echols, Y Matsunaga… - The Lancet Infectious …, 2021 - thelancet.com
Background New antibiotics are needed for the treatment of patients with life-threatening
carbapenem-resistant Gram-negative infections. We assessed the efficacy and safety of …
carbapenem-resistant Gram-negative infections. We assessed the efficacy and safety of …
Treatment of critically ill patients with cefiderocol for infections caused by multidrug-resistant pathogens: review of the evidence
P Viale, CE Sandrock, P Ramirez, GM Rossolini… - Annals of intensive …, 2023 - Springer
Appropriate antibiotic treatment for critically ill patients with serious Gram-negative infections
in the intensive care unit is crucial to minimize morbidity and mortality. Several new …
in the intensive care unit is crucial to minimize morbidity and mortality. Several new …
Cefiderocol: a review in serious Gram-negative bacterial infections
YY Syed - Drugs, 2021 - Springer
Abstract Intravenous cefiderocol (Fetroja®; Fetcroja®) is the first siderophore cephalosporin
approved for the treatment of adults with serious Gram-negative bacterial infections …
approved for the treatment of adults with serious Gram-negative bacterial infections …
Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised …
S Portsmouth, D van Veenhuyzen, R Echols… - The Lancet Infectious …, 2018 - thelancet.com
Summary Background Carbapenem-resistant Gram-negative bacteria represent the highest
priority for addressing global antibiotic resistance. Cefiderocol (S-649266), a new …
priority for addressing global antibiotic resistance. Cefiderocol (S-649266), a new …
In vitro activity of cefiderocol and comparators against carbapenem-resistant Gram-negative pathogens from France and Belgium
S Oueslati, P Bogaerts, L Dortet, S Bernabeu… - Antibiotics, 2022 - mdpi.com
Infections with carbapenem-resistant (CR) Gram-negative (GN) pathogens have increased
in many countries worldwide, leaving only few therapeutic options. Cefiderocol (CFDC) is …
in many countries worldwide, leaving only few therapeutic options. Cefiderocol (CFDC) is …
Cefiderocol-based combination therapy for “difficult-to-treat” gram-negative severe infections: real-life case series and future perspectives
DF Bavaro, A Belati, L Diella, M Stufano, F Romanelli… - Antibiotics, 2021 - mdpi.com
Cefiderocol is a new cephalosporin displaying against extensively resistant (XDR) Gram-
negative bacteria. We report our experience with cefiderocol-based combination therapies …
negative bacteria. We report our experience with cefiderocol-based combination therapies …
In Vitro Activity of Cefiderocol against US and European Gram-Negative Clinical Isolates Collected in 2020 as Part of the SENTRY Antimicrobial Surveillance …
D Shortridge, JM Streit, R Mendes… - Microbiology …, 2022 - Am Soc Microbiol
Cefiderocol is a siderophore-conjugated cephalosporin with broad activity against Gram-
negative (GN) bacteria, including carbapenem-resistant Enterobacterales (CRE) …
negative (GN) bacteria, including carbapenem-resistant Enterobacterales (CRE) …
[HTML][HTML] Clinical data from studies involving novel antibiotics to treat multidrug-resistant Gram-negative bacterial infections
Abstract Multidrug-resistant (MDR) Gram-negative bacteria (GNB) pose a critical threat to
global healthcare, worsening outcomes and increasing mortality among infected patients …
global healthcare, worsening outcomes and increasing mortality among infected patients …
Cefiderocol for the treatment of infections due to metallo-B-lactamase–producing pathogens in the CREDIBLE-CR and APEKS-NP phase 3 randomized studies
In the CREDIBLE-CR and APEKS-NP studies, cefiderocol treatment was effective against
gram-negative bacteria producing metallo-B-lactamases; rates of clinical cure …
gram-negative bacteria producing metallo-B-lactamases; rates of clinical cure …
Cefiderocol for extensively drug-resistant gram-negative bacterial infections: real-world experience from a case series and review of the literature
S Zingg, GJ Nicoletti, S Kuster, M Junker… - Open forum …, 2020 - academic.oup.com
Cefiderocol is a new siderophore cephalosporin with activity against carbapenem-resistant
gram-negative bacteria. Data on its clinical efficacy are limited to complicated urinary tract …
gram-negative bacteria. Data on its clinical efficacy are limited to complicated urinary tract …